GlobeNewswire

ING to file 2020 Annual Report on Form 20-F

Share

ING to file 2020 Annual Report on Form 20-F

ING will today file its Annual Report on Form 20-F for the year ended 31 December 2020 with the United States Securities and Exchange Commission (SEC). The 2020 Form 20-F will be available on the ING website, and can be downloaded from the SEC website (www.sec.gov) later today. Shareholders or holders of ADRs can also request a hard copy of ING’s audited financial statements, free of charge, at www.ing.com/publications.htm

Note for editors

For further information on ING, please visit www.ing.com. Frequent news updates can be found in the Newsroom or via the @ING_news Twitter feed. Photos of ING operations, buildings and its executives are available for download at Flickr. ING presentations are available at SlideShare.

Press enquiries Investor enquiries
Raymond VermeulenING Group Investor Relations
+31 20 576 6369+31 20 576 6396
Raymond.Vermeulen@ing.comInvestor.Relations@ing.com

ING Profile

ING is a global financial institution with a strong European base, offering banking services through its operating company ING Bank. The purpose of ING Bank is empowering people to stay a step ahead in life and in business. ING Bank’s more than 57,000 employees offer retail and wholesale banking services to customers in over 40 countries.

ING Group shares are listed on the exchanges of Amsterdam (INGA NA, INGA.AS), Brussels and on the New York Stock Exchange (ADRs: ING US, ING.N).

Sustainability forms an integral part of ING’s strategy, evidenced by ING’s leading position in sector benchmarks by Sustainalytics and MSCI and our ‘A-list’ rating by CDP. ING Group shares are included in major sustainability and Environmental, Social and Governance (ESG) index products of leading providers STOXX, Morningstar and FTSE Russell. In January 2021, ING received an ESG evaluation score of 83  ('strong') from S&P Global Ratings.

Important legal information

Elements of this press release contain or may contain information about ING Groep N.V. and/ or ING Bank N.V. within the meaning of Article 7(1) to (4) of EU Regulation No 596/2014.

Certain of the statements contained herein are not historical facts, including, without limitation, certain statements made of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Actual results, performance or events may differ materially from those in such statements due to a number of factors, including, without limitation: (1) changes in general economic conditions, in particular economic conditions in ING’s core markets, including changes affecting currency exchange rates, (2) the effects of the Covid-19 pandemic and related response measures, including lockdowns and travel restrictions, on economic conditions in countries in which ING operates, on ING’s business and operations and on ING’s employees, customers and counterparties, (3) changes affecting interest rate levels, (4) any default of a major market participant and related market disruption, (5) changes in performance of financial markets, including in Europe and developing markets, (6) political instability and fiscal uncertainty in Europe and the United States, (7) discontinuation of or changes in ‘benchmark’ indices, (8) inflation and deflation in our principal markets, (9) changes in conditions in the credit and capital markets generally, including changes in borrower and counterparty creditworthiness, (10) failures of banks falling under the scope of state compensation schemes, (11) non-compliance with or changes in laws and regulations, including those financial services and tax laws, and the interpretation and application thereof, (12) geopolitical risks, political instabilities and policies and actions of governmental and regulatory authorities, (13) legal and regulatory risks in certain countries with less developed legal and regulatory frameworks, (14) prudential supervision and regulations, including in relation to stress tests and regulatory restrictions on dividends and distributions,, (also among members of the group), (15) regulatory consequences of the United Kingdom’s withdrawal from the European Union, including authorizations and equivalence decisions, (16) ING’s ability to meet minimum capital and other prudential regulatory requirements, (17) changes in regulation of US commodities and derivatives businesses of ING and its customers, (18) application of bank recovery and resolution regimes, including write-down and conversion powers in relation to our securities, (19) outcome of current and future litigation, enforcement proceedings, investigations or other regulatory actions, including claims by customers who feel mislead and other conduct issues, (20) changes in tax laws and regulations and risks of non-compliance or investigation in connection with tax laws, including FATCA, (21) operational risks, such as system disruptions or failures, breaches of security, cyber-attacks, human error, changes in operational practices or inadequate controls including in respect of third parties with which we do business, (22) risks and challenges related to cybercrime including the effects of cyber-attacks and changes in legislation and regulation related to cybersecurity and data privacy, (23) changes in general competitive factors, including ability to increase or maintain market share, (24) the inability to protect our intellectual property and infringement claims by third parties, (25) inability of counterparties to meet financial obligations or ability to enforce rights against such counterparties, (26) changes in credit ratings, (27) business, operational, regulatory, reputation and other risks and challenges in connection with climate change, (28) inability to attract and retain key personnel, (29) future liabilities under defined benefit retirement plans, (30) failure to manage business risks, including in connection with use of models, use of derivatives, or maintaining appropriate policies and guidelines, (31) changes in capital and credit markets, including interbank funding, as well as customer deposits, which provide the liquidity and capital required to fund our operations, and (32) the other risks and uncertainties detailed in the most recent annual report of ING Groep N.V. (including the Risk Factors contained therein) and ING’s more recent disclosures, including press releases, which are available on www.ING.com.

This document may contain inactive textual addresses to internet websites operated by us and third parties. Reference to such websites is made for information purposes only, and information found at such websites is not incorporated by reference into this annual report. ING does not make any representation or warranty with respect to the accuracy or completeness of, or take any responsibility for, any information found at any websites operated by third parties. ING specifically disclaims any liability with respect to any information found at websites operated by third parties. ING cannot guarantee that websites operated by third parties remain available following the filing of this document or that any information found at such websites will not change following the filing of this document. Many of those factors are beyond ING’s control.

Any forward looking statements made by or on behalf of ING speak only as of the date they are made, and ING assumes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information or for any other reason.

This document does not constitute an offer to sell, or a solicitation of an offer to purchase, any securities in the United States or any other jurisdiction.

Attachment


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Immunicum Announces Presentations at Upcoming Scientific Conferences in April and May19.4.2021 08:00:00 CEST | Press release

Press Release 19 April 2021 Immunicum Announces Presentations at Upcoming Scientific Conferences in April and May Immunicum AB (publ) today announced that it will participate and deliver multiple presentations featuring its proprietary Phase II clinical candidates, immune primer ilixadencel and cancer relapse vaccine DCP-001, at the following upcoming scientific conferences: Neoantigen Summit Europe, April 20 – 22, 2021 Alex Karlsson-Parra, Chief Scientific Officer at Immunicum, will make an oral presentation on “Harnessing the immune-priming function of allogeneic dendritic cells in neoantigen-based vaccines”, on Wednesday, April 21st at 2:45 pm CET / 8:45 am ET. Cancer Immunotherapy (CIMT) Annual Meeting, May 10 – 12, 2021. Alex Karlsson-Parra will deliver an oral presentation on “Combining intratumoral administration of inflammatory allogeneic DCs with systemic anti-CTLA-4 treatment leads to tumor eradication and is associated with peripheral expansion of CD8+ effector cells with a

Immunicum tillkännager presentationer vid kommande vetenskapliga möten i april och maj19.4.2021 08:00:00 CEST | Pressemelding

Pressrelease 19 april 2021 Immunicum tillkännager presentationer vid kommande vetenskapliga möten i april och maj Immunicum AB (publ) meddelade idag att bolaget kommer att delta och göra ett flertal presentioner gällande sina två program i klinisk fas II-utveckling, immunprimern ilixadencel och canceråterfallsvaccinet DCP-001 vid nedanstående vetenskapliga möten: Neoantigen Summit Europe, 20 – 22 april, 2021 Alex Karlsson-Parra, Chief Scientific Officer, Immunicum håller ett anförande på temat ” “Harnessing the immune-priming function of allogeneic dendritic cells in neoantigen-based vaccines”, onsdagen den 21 april kl. 14.45 CET/8.45 ET. Cancer Immunotherapy (CIMT) Annual Meeting, 10-12 maj, 2021 Alex Karlsson-Parra, Chief Scientific Officer, Immunicum håller ett anförande på temat “Combining intratumoral administration of inflammatory allogeneic DCs with systemic anti-CTLA-4 treatment leads to tumor eradication and is associated with peripheral expansion of CD8+ effector cells with a

ABN AMRO accepted settlement offer in the anti-money laundering investigation in the Netherlands19.4.2021 07:30:00 CEST | Press release

ABN AMRO accepted settlement offer in the anti-money laundering investigation in the Netherlands Today ABN AMRO Bank N.V. (ABN AMRO) announced that it has accepted a settlement offer from the Dutch Public Prosecution Service (DPPS) in connection with the previously announced investigation by the DPPS into ABN AMRO's compliance with its obligations under the Dutch Anti-Money Laundering and Counter Terrorism Financing Act (Wet ter voorkoming van witwassenen financiering van terrorisme, AML/CTF Act) between 2014 and 2020. As part of this settlement, ABN AMRO will pay EUR 480 million. ABN AMRO fully cooperated with the DPPS throughout the investigation. Based on the investigation, the DPPS identified serious shortcomings in ABN AMRO's processes to combat money laundering in the Netherlands, such as the client acceptance, transaction monitoring and client exit processes (the so-called 'Client Life Cycle' processes) in the period between 2014 and 2020, as a result of which, in certain instan

Nyxoah Announces Submission of Draft Registration Statement For Proposed Public Listing in the United States19.4.2021 07:02:32 CEST | Press release

REGULATED INFORMATION INSIDE INFORMATION Nyxoah Announces Submission of Draft Registration Statement For Proposed Public Listing in the United States Mont-Saint-Guibert, Belgium – 19 April 2021 – Nyxoah SA (Euronext Brussels: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that it has confidentially submitted a draft Registration Statement on Form F-1 to the Securities and Exchange Commission (the "SEC") relating to the proposed public offering of its ordinary shares in the United States. The number of ordinary shares to be offered and the price for the proposed offering have not yet been determined. The public offering is expected to take place after the SEC completes its review process, subject to market and other conditions. This announcement is being made pursuant to, and in accordance with, Rule 135 under the Securities Act of 1933, as am

Millicom signs agreements to conclude Africa divestiture program19.4.2021 06:05:00 CEST | Press release

Millicomsigns agreements to conclude Africa divestiture program Luxembourg,April19, 2021 – Millicom International Cellular S.A. (“Millicom”) announces that it has signed agreements for the sale of its operations in Tanzania and for its stake in the AirtelTigo joint venture in Ghana. Once closed, the transactions will complete Millicom’s multi-year plan to divest its African operations and focus on its Latin America markets. In Tanzania, Millicom has agreed to sell its entire operations to a consortium led by Axian, a pan-African group that was part of the consortium that acquired Millicom’s operations in Senegal in 2018. In Ghana, Millicom along with its joint venture partner, Bharti Airtel Limited, have signed a definitive agreement for the transfer of AirtelTigo to the Government of Ghana. Millicom will take a $25 million charge as a result of this agreement. Millicom CEO, Mauricio Ramos, commented: “Today Tigo is a leading provider of broadband services to consumers, businesses and

Nokia to deploy indoor 5G small cells solutions with LG Uplus in South Korea19.4.2021 03:00:00 CEST | Press release

Press Release Nokia to deploy indoor 5G small cells solutions with LG Uplus in South Korea Nokia will expand and enhance LG Uplus’ 5G network, enabling seamless 5G connectivity between indoor and outdoor locationsLG Uplus will use Nokia’s AirScale indoor solution which can be deployed flexibly and upgraded easily The deal continues the long-standing partnership between the two companies 19 April 2021 Espoo, Finland – Nokia today announced an agreement with LG Uplus to expand 5G coverage by installing new equipment from Nokia’s comprehensive AirScale portfolio across the country, enabling seamless 5G indoor and outdoor connectivity. The dealis expected to accommodate future network expansion and will further deepen the partnership between the two companies, which have already collaborated on LTE, 5G and digital projects. Being the first deployment of its kind in South Korea, Nokia will install its cost-effective, next-generation small cell AirScale Indoor (ASiR) systems in a range of in